AliveCor, an innovator in FDA-cleared personal electrocardiogram (ECG) technology, has partnered with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.
Tomas Nevesely Shutterstock
694514749
opioids
In the six-month pilot study, healthcare professionals will use KardiaMobile 6L, a medical-grade, six-lead personal ECG device that is FDA-cleared to measure QTc intervals, to detect QT prolongation, a potentially dangerous side effect associated with certain medications like methadone.
Patricia Baran, senior vice president, Enterprise North America & Biopharma Worldwide, said: “We are excited to partner with Thomas Jefferson University Hospital on this important study that will illuminate the benefits of real-time QTc interval monitoring with KardiaMobile 6L on patients’ outcomes and their treatment experience. By enabling clinicians to efficiently detect cardiac side effects, they can better counsel patients about taking the appropriate steps to mitigate risks to their heart health.”
William Jangro, DO, medical director, Jefferson NARP, added: “Rapid, point-of-care devices can have an important role in streamlining the cardiac safety monitoring required by many behavioural disorder medicines, which are a critical part of comprehensive treatment strategies for people with substance use disorders.”
Daniel Frisch, MD, associate professor of Medicine Electrophysiology Section, Thomas Jefferson University Hospital, commented: “We look forward to assessing how efficient QTc monitoring with KardiaMobile 6L increases compliance with guideline recommendations, improves the patient experience, enhances treatment, and allows for interdepartmental collaboration.”
KardiaMobile 6L was cleared by the FDA in July 2021 for use by healthcare professionals to calculate patients’ QTc interval.
